A Randomized, Double-Blind, Phase 2 Trial of Paclitaxel Plus Bevacizumab and Enzastaurin Versus Paclitaxel Plus Bevacizumab and Placebo for Locally Recurrent or Metastatic Breast Cancer

Inclusion Criteria:

- Must have signed an inform consent document

- Have histologic or cytologic diagnosis of breast cancer with evidence of unresectable
locally recurrent or metastatic disease

- Have not received any prior chemotherapy for locally recurrent or metastatic disease

- Have not had adjuvant or neoadjuvant taxane therapy within 12 months prior to
assignment to study treatment

- Age 18 years or older at time of informed consent

Exclusion Criteria:

- Have any clinical evidence of central nervous system (CNS) metastases

- Have a history of seizure

- Have had a major surgical procedure within 4 weeks prior to assignment to study
treatment

- Have had a minor surgical procedure, placement of an access device, or fine needle
aspiration within 7 days prior to assignment to study treatment

- Have symptomatic peripheral vascular disease